William Meury
CIK 1536778 · Chief Executive Officer · last filed 2026-07-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
909 THIRD AVENUE
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INCY | Chief Executive Officer | 183,129 | $116.79 | $21.39M | $0 | 5 | 2026-07-20 |
| SNDX | Director | 90,000 | $13.35 | $1.20M | -$1.70M | 9 | 2025-02-07 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | President and CEO | 19,037 | $329.83 | $6.28M | $0 | 4 | 2024-03-18 |
| Allergan plc (AGN) Delisted | EVP & Chief Commercial Officer | 0 | — | — | -$15.29M | 18 | 2020-05-11 |
| ACT | See Remarks | 71,194 | $46.73 | $3.33M | $0 | 2 | 2015-05-19 |
| Forest Laboratories, LLC (FRX) Delisted | EVP - Sales and Marketing | 87,542 | $12.00 | $1.05M | -$2.28M | 11 | 2013-12-10 |
Recent Filings · Page 2 of 6
55 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-08-03 | SNDX | Mixed | — | -$1.03M | EDGAR |
| 2023-08-02 | SNDX | Notice (144) | −83,000 | -$1.70M | EDGAR |
| 2023-02-03 | SNDX | Grant (A) | +16,000 | $0 | EDGAR |
| 2023-01-05 | Karuna Therapeutics, Inc. (KRTX) Delisted | Grant (A) | +38,073 | $0 | EDGAR |
| 2022-02-03 | SNDX | Grant (A) | +16,000 | $0 | EDGAR |
| 2021-02-05 | SNDX | Grant (A) | +16,000 | $0 | EDGAR |
| 2020-05-11 | Allergan plc (AGN) Delisted | Disp (D) | −32,635 | $0 | EDGAR |
| 2020-04-07 | Allergan plc (AGN) Delisted | Tax (F) | −855 | -$150.2K | EDGAR |
| 2020-03-04 | Allergan plc (AGN) Delisted | Grant (A) | +21,667 | $4.20M | EDGAR |
| 2020-02-14 | SNDX | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.